Cellectar Biosciences Targets 2027 EU Launch for Iopofosine I 131

Cellectar Biosciences has reached a critical inflection point as it concludes its 2025 fiscal year, positioning itself as a formidable contender in the rapidly evolving radiopharmaceutical landscape. The company’s announcement of its year-end financial results and corporate updates underscores a strategic shift toward commercial readiness, particularly in the European market. At the heart of this transition is iopofosine I 131, a first-in-class phospholipid drug conjugate (PDC) designed to deliver iodine-131 directly to cancer cells while sparing healthy tissue.

The company’s commitment to a Q3 2026 submission for Conditional Marketing Authorization (CMA) to the European Medicines Agency (EMA) is a definitive milestone. This timeline suggests a potential commercial launch in the European Union by 2027, specifically targeting Waldenström Macroglobulinemia (WM), a rare and slow-growing type of non-Hodgkin lymphoma. The regulatory path for iopofosine I 131 is bolstered by what management describes as a strong clinical dataset and ongoing, productive dialogues with both the EMA and the U.S. Food and Drug Administration (FDA). For investors and clinicians, the focus on WM represents a savvy entry point into the market, addressing an orphan indication with significant unmet need before potentially expanding into broader hematologic and solid tumor indications.

“

At the heart of this transition is iopofosine I 131, a first-in-class phospholipid drug conjugate (PDC) designed to deliver iodine-131 directly to cancer cells while sparing healthy tissue.

Beyond its lead asset, Cellectar is aggressively diversifying its pipeline through its proprietary PDC platform. The initiation of the Phase 1b dose-finding study for CLR 125 in triple-negative breast cancer (TNBC) is a notable expansion into solid tumors. TNBC remains one of the most challenging subtypes of breast cancer to treat due to the lack of estrogen, progesterone, and HER2 receptors, which limits the efficacy of standard targeted therapies. By applying its radiotherapeutic platform to TNBC, Cellectar is testing the versatility of its phospholipid delivery mechanism. Early data from this study is anticipated by mid-2026, a catalyst that could significantly de-risk the company’s solid tumor strategy and validate the broader utility of the PDC technology.

Operational excellence was a recurring theme in CEO James Caruso’s year-end commentary. The company spent 2025 not only advancing clinical trials but also fortifying its intellectual property estate and supply chain infrastructure. In the radiopharmaceutical sector, supply chain resilience is a critical competitive advantage, given the complexities of handling and transporting radioactive isotopes with short half-lives. By strengthening these foundational elements, Cellectar is preparing for the logistical demands of a commercial-scale rollout, a hurdle that has historically challenged other players in the space.